Kura OncologyKURA
KURA
About: Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.
Employees: 142
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
29% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 17
27% more call options, than puts
Call options by funds: $853K | Put options by funds: $671K
17% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 53
3% more funds holding
Funds holding: 173 [Q2] → 178 (+5) [Q3]
0.78% more ownership
Funds ownership: 107.38% [Q2] → 108.16% (+0.78%) [Q3]
5% less capital invested
Capital invested by funds: $1.68B [Q2] → $1.61B (-$76.7M) [Q3]
17% less funds holding in top 10
Funds holding in top 10: 6 [Q2] → 5 (-1) [Q3]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$19
114%
upside
Avg. target
$29
224%
upside
High target
$37
318%
upside
6 analyst ratings
5 positive
83%
1 neutral
17%
0 negative
0%
B of A Securities Jason Zemansky 55% 1-year accuracy 6 / 11 met price target | 227%upside $29 | Buy Maintained | 22 Nov 2024 |
Jefferies Roger Song 19% 1-year accuracy 3 / 16 met price target | 216%upside $28 | Buy Maintained | 21 Nov 2024 |
HC Wainwright & Co. Joseph Pantginis 21% 1-year accuracy 81 / 386 met price target | 318%upside $37 | Buy Maintained | 21 Nov 2024 |
JMP Securities Reni Benjamin 8% 1-year accuracy 3 / 36 met price target | 261%upside $32 | Market Outperform Reiterated | 19 Nov 2024 |
UBS David Dai 18% 1-year accuracy 2 / 11 met price target | 205%upside $27 | Buy Initiated | 24 Oct 2024 |
Financial journalist opinion
Based on 4 articles about KURA published over the past 30 days
Positive
Seeking Alpha
1 week ago
Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)
Kura Oncology, Inc.'s collaboration with Kyowa Kirin brings $330M upfront and a potential $1.2B in milestone payments, enhancing long-term shareholder value despite initial market disappointment. Ziftomenib, Kura's lead candidate, shows promising results in AML treatment, with a 35% complete remission rate, and could address up to 50% of AML patients. The stock is upgraded to Strong Buy due to its deep value, strong pipeline performance, and potential for substantial upside if FDA approval and commercialization go according to plan.
Neutral
GlobeNewsWire
2 weeks ago
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting
– Interim analysis from Phase 1a portion of KOMET-007 shows 100% CR rate in NPM1-m and 83% CR rate in KMT2A-r 1L adverse risk AML with 7+3 –
Neutral
GlobeNewsWire
3 weeks ago
Kura Oncology to Host Virtual Investor Event on December 9, 2024
Live webcast and conference call to discuss presentation of updated data from KOMET-007 combination trial of ziftomenib at ASH Live webcast and conference call to discuss presentation of updated data from KOMET-007 combination trial of ziftomenib at ASH
Neutral
GlobeNewsWire
4 weeks ago
Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the upcoming JMP Securities Hematology and Oncology Summit. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 2:00 p.m. ET / 11:00 a.m. PT on December 2, 2024.
Negative
Investors Business Daily
1 month ago
Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26%
Kura Oncology slammed the door on its takeover narrative Thursday, inking a deal for its leukemia drug. Kura stock crashed.
Positive
Reuters
1 month ago
Kura Oncology to partner with Kyowa Kirin for blood cancer therapy
Kura Oncology said on Wednesday it will collaborate with Japan's Kyowa Kirin to develop and commercialize the blood cancer therapy ziftomenib.
Neutral
PRNewsWire
1 month ago
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors – – Companies to jointly develop and commercialize ziftomenib; 50/50 profit share in the U.S.; Kura to lead U.S. development and commercial activities and book sales; Kyowa Kirin has exclusive commercialization rights outside the U.S. – – Companies to jointly pursue broad development program targeting acute leukemias, including frontline indications, combinations with targeted therapies and post-transplant maintenance setting – – Kura anticipates collaboration funding along with current cash balance to support AML program advances through commercialization in frontline combination therapy – SAN DIEGO and TOKYO , Nov. 20, 2024 /PRNewswire/ -- Kura Oncology, Inc. (Nasdaq: KURA) and Kyowa Kirin Co., Ltd. (TSE: 4151) today announced they have entered into a global strategic collaboration to develop and commercialize ziftomenib, Kura's selective oral menin inhibitor, being investigated for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies.
Neutral
GlobeNewsWire
1 month ago
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors –
Neutral
Seeking Alpha
1 month ago
Kura Oncology, Inc. (KURA) Q3 2024 Earnings Call Transcript
Kura Oncology, Inc. (NASDAQ:KURA ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Pete De Spain - Head, Investor Relations Dr. Troy Wilson - President and CEO Tom Doyle - Senior Vice President, Finance and Accounting Dr. Mollie Leoni - Executive Vice President, Clinical Development Conference Call Participants Li Watsek - Cantor Jonathan Chang - Leerink Partners Jason Zemansky - Bank of America Roger Song - Jefferies Charles Zhu - LifeSci Capital Phil Nadeau - TD Cowen Peter Lawson - Barclays Justin Zelin - BTIG Brad Canino - Stifel Operator Good afternoon, ladies and gentlemen. Welcome to the Kura Oncology Third Quarter 2024 Financial Results Call.
Neutral
GlobeNewsWire
1 month ago
Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r adverse risk AML patients selected for oral presentation on Saturday, December 7th –
Charts implemented using Lightweight Charts™